Benuvia Enters into Partnership with Cannovation Clinical Research Partners to Provide Integrated Solutions for Controlled-Substance Therapeutics
Thursday, December 04, 2025
Benuvia Operations has entered into a strategic partnership with Cannovation Clinical Research Partners (CCRP).
The collaboration aims to create the industry’s first fully integrated platform that combines manufacturing and contract research services for Schedule I–V substances.
The partnership brings together Benuvia’s capabilities in controlled-substance manufacturing, analytical testing and CMC development with CCRP’s expertise in preclinical and clinical research, regulatory planning and global trial management. This combined approach offers pharmaceutical and biotechnology sponsors a single, compliant route from early development to commercialisation for cannabinoid, psychedelic and other emerging CNS therapeutics.
Traditionally, companies developing controlled-substance medicines have had to manage multiple vendors for research, regulatory support and GMP manufacturing, often resulting in delays and operational challenges. Through this new collaboration, sponsors will benefit from streamlined transitions from IND to clinical trials, improved timelines through reduced vendor fragmentation, and harmonised compliance across the development cycle.
The partnership also provides access to global clinical trial networks across North America, Europe and Latin America, along with fully licensed Schedule I–V manufacturing for substances such as psilocybin, LSD, DMT and other CNS candidates. Additional commercialisation support is included to help ensure the safe and compliant delivery of new therapies.
With interest in psychedelic and cannabinoid-based treatments continuing to grow—particularly for conditions such as depression, PTSD and substance-use disorders—demand for specialised and compliant infrastructure is increasing.
The collaboration positions both organisations to support this expanding field by offering a coordinated, efficient and globally accessible development pathway for next-generation controlled-substance therapeutics.
